Zhejiang Jolly Pharmaceutical Co.,LTD
300181.SZ
Shenzhen Stock Exchange14.37
CNY
+0.20
- -
Zhejiang Jolly Pharmaceutical Co.,LTD
300181.SZ
(Shenzhen Stock Exchange)
Recent
price
14.37
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Zhejiang Jolly Pharmaceutical Co.,LTD is a national high-tech pharmaceutical enterprise engaged in the research, production, and marketing of traditional Chinese medicinal products and related pharmaceutical preparations. The company manufactures and sells core products including Wuling series products such as Wuling capsules and Wuling powder, Lingze tablets for benign prostatic hyperplasia, Linglianhua particles for menopausal syndrome treatment, Bailing tablets containing fermented cordyceps sinensis for respiratory and kidney-related conditions, and other traditional Chinese medicine tablets and granules. It also produces and markets a range of injections such as azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside injections. The company incorporates modern bio-fermentation technology with traditional Chinese medicinal fungi, including the industrialized production of Wulingshen-based products and cordyceps fermentation powders. Founded in 2000 and headquartered in Huzhou, Zhejiang Province, China, Zhejiang Jolly Pharmaceutical operates with several subsidiaries such as Qinghai Everest Cordyceps Sinensis Pharmaceutical and Zhejiang Kaixin Medicine, and holds investments in medical services like those provided by Deqing No.3 People’s Hospital. It is listed on the Shenzhen Stock Exchange's Growth Enterprises Market under ticker 300181.SZ. In recent major developments, the company announced plans to raise up to 1.6 billion yuan via bond issuance to fund projects and strengthen capital resources, indicating a strategic expansion of its operational capabilities. In 2024, Zhejiang Jolly Pharmaceutical acquired a controlling stake in Lingyi (Hangzhou) Biotechnology, a gene therapy drug developer, enabling collaboration on the development and sales of neurological disease treatments including drugs for Parkinson's disease and Alzheimer's disease. Additionally, the company completed an acquisition of an 8% stake in Zhejiang Top Medicine Co., Ltd., signifying ongoing efforts to broaden its pharmaceutical portfolio and market reach. Zhejiang Jolly Pharmaceutical's business spans traditional Chinese medicine research and production, pharmaceutical biofermentation, and clinical medicine development and sales across China and internationally. The company emphasizes innovation in medicinal fungi pharmaceutical technology through its provincial high-tech research centers and national local co-operational engineering lab. Its targeted markets include hospitals, clinics, and pharmaceutical distribution networks focused on therapeutic areas such as respiratory health, neurological diseases, benign prostatic hyperplasia, and menopausal health. With a comprehensive production infrastructure covering raw materials, tablets, capsules, particles, and freeze-dried powder injections, Zhejiang Jolly Pharmaceutical maintains a significant presence in the Chinese pharmaceutical industry and is actively expanding its business scope through strategic investments and product development initiatives.